Birdwatch Note
2024-11-14 12:36:19 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
あたかもコスタイベ(レプリコンワクチン)が世界中で開発中止、申請取下、承認却下等が行われているかのような言説ですが、そのような事実はありません(p.6,53) https://www.mhlw.go.jp/content/10601000/001305553.pdf コスタイベの安全性と有効性は治験で良好と評価されています。 死亡はプラセボ群が16(COVID19:9)に対して接種群では5(COVID19:1)と減少しており、特段の懸念は認められません https://doi.org/10.1038/s41467-024-47905-1 https://www.mhlw.go.jp/content/10906000/001316061.pdf https://www.pmda.go.jp/drugs/2024/P20240917001/780009000_30500AMX00282_A100_1.pdf https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#20 IF値の高い医学誌・科学誌の査読済論文、WHOや先進国民主主義の政府機関の公式発表等の原典を参照しましょう。 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#34 https://togetter.com/li/2416068 https://togetter.com/li/2131189 https://togetter.com/li/2174198
Written by EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1856894141126635815
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1857039861720449092
- noteId - 1857039861720449092
- participantId -
- noteAuthorParticipantId - EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00 Participant Details
- createdAtMillis - 1731587779822
- tweetId - 1856894141126635815
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- あたかもコスタイベ(レプリコンワクチン)が世界中で開発中止、申請取下、承認却下等が行われているかのような言説ですが、そのような事実はありません(p.6,53) https://www.mhlw.go.jp/content/10601000/001305553.pdf コスタイベの安全性と有効性は治験で良好と評価されています。 死亡はプラセボ群が16(COVID19:9)に対して接種群では5(COVID19:1)と減少しており、特段の懸念は認められません https://doi.org/10.1038/s41467-024-47905-1 https://www.mhlw.go.jp/content/10906000/001316061.pdf https://www.pmda.go.jp/drugs/2024/P20240917001/780009000_30500AMX00282_A100_1.pdf https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#20 IF値の高い医学誌・科学誌の査読済論文、WHOや先進国民主主義の政府機関の公式発表等の原典を参照しましょう。 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#34 https://togetter.com/li/2416068 https://togetter.com/li/2131189 https://togetter.com/li/2174198
Note Ratings
| rated at | rated by | |
| 2024-11-14 17:55:13 -0600 | Rating Details | |
| 2024-11-14 17:23:28 -0600 | Rating Details | |
| 2024-11-14 14:34:22 -0600 | Rating Details | |
| 2024-11-14 09:27:48 -0600 | Rating Details | |
| 2024-11-14 09:21:26 -0600 | Rating Details | |
| 2024-11-14 08:50:40 -0600 | Rating Details | |
| 2024-11-14 07:55:54 -0600 | Rating Details | |
| 2024-11-14 07:53:02 -0600 | Rating Details | |
| 2024-11-14 07:47:32 -0600 | Rating Details | |
| 2024-11-14 07:46:46 -0600 | Rating Details | |
| 2024-11-14 07:34:49 -0600 | Rating Details | |
| 2024-11-14 07:29:45 -0600 | Rating Details | |
| 2024-11-14 07:29:44 -0600 | Rating Details | |
| 2024-11-14 07:28:24 -0600 | Rating Details | |
| 2024-11-14 07:27:48 -0600 | Rating Details | |
| 2024-11-14 07:25:25 -0600 | Rating Details | |
| 2024-11-14 07:20:18 -0600 | Rating Details | |
| 2024-11-14 07:07:20 -0600 | Rating Details | |
| 2024-11-15 17:58:13 -0600 | Rating Details | |
| 2024-11-15 00:49:41 -0600 | Rating Details | |
| 2024-11-14 20:29:42 -0600 | Rating Details | |
| 2024-11-14 19:12:24 -0600 | Rating Details | |
| 2024-11-14 10:53:56 -0600 | Rating Details | |
| 2024-11-14 07:50:13 -0600 | Rating Details | |
| 2024-11-14 07:34:14 -0600 | Rating Details | |
| 2024-11-14 07:30:36 -0600 | Rating Details | |
| 2024-11-14 07:03:04 -0600 | Rating Details |